STK11 and neoplasm: For instance, patients with STK11 mutations, which are associated with an immunosuppressive tumour microenvironment (TME), can be stratified and treated with combination therapies that include immune checkpoint inhibitors (ICIs) and metabolic modulators to counteract the metabolic reprogramming that promotes resistance [181,182].